Abstract: Availability of X-ray crystal structure of 3C protease of several enteroviruses provided an opportunity for in silico drug design and development approach. Presented study is aimed at designing a novel compound targeting 3C protease of Coxsackievirus (CVB3), which is reported frequently to cause myocarditis in North America and Europe. A pthalimido-sulfonamide derivative (ZINC13799063) was identified through high-throughput virtual screening (HTVS) approach from the top HITs. A small library of phalimido-sulphonamides was enumerated to find a potential LEAD. Compound 17 from the library was found to inhibit CVB3 selectively in cell based antiviral assay at a concentration of EC50=1.0±0.1 µM with a selectivity index of >140. Molecular dynamics study was performed to investigate the selective inhibition of CVB3 over CVB4.
Introduction
Coxsackie virus (CV), a non-enveloped RNA virus belonging to the genus Enterovirus of family Picornaviridae 1 was isolated in the year 1947 2, 3 . The first major outbreak was reported in Johannesburg during 1952 that was followed by regular flare-ups every 3-6 years 4, 5 . Coxsackie viral infection in human being has been associated with myocarditis, myopericarditis, aseptic meningitis and chronic autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM) [6] [7] [8] . A chronic form of the infection in females may lead to new born babies with neonatal myocarditis and/or hepatitis 9, 10 . Currently, there is no specific antiviral therapy available for the treatment of infections with this virus 5 . Although many molecules with in vitro antiviral activity have been reported in the literature, none has made it to the market. Worth mentioning a few: 1,2-fluoro-4-(2-methyl-8-(3-(methylsulfonyl)-benzylamino) imidazo [1,2-a]pyrazin-3-yl)phenol 11 , pyrrolidine dithiocarbamate 12 , 5-substituted cytidine analogues 13 . Many molecules from plants origin were also reported to have inhibitory activity on CV, few to mention: (i) benzophenone C-glucosides and gallotannins from mango tree stem bark 14 , macromolecules isolated from Phellinus pini fruiting body 15 , roots of Phyllanthus emblica 16 , and monomers from Chinese medicinal herb Folium isatidis 17 . Enteroviral 3C protease belongs to trypsin-like cysteine proteases 18 . The active site of the proteases was having catalytic triad composed of His40, Glu71 and Cys147 and is conserved across picornaviruses. It is an essential multifunctional enzyme that processes nine intermediate processing events of viral cell cycle in all picornaviruses 19 . In addition, it also shuts off host cell RNA transcription 20 , and targets several host proteins such as translation initiation factor G, and cleavage stimulation factor 64 to stop host protein synthesis and induce apoptosis [21] [22] [23] . As proteases of enteroviruses are having little sequence similarity with host cell proteases 24 , designing molecule to hit them has been a rational approach in developing antivirals against them.
As X-ray crystal structure of 3C protease of CVB3 (PDB: 3ZZA) is available, a high-throughput virtual screening (HTVS) approach has been adopted to identify new hit compounds for drug development project. The approach (HTVS) has been successful in many cases and the readers are suggested to refer the review by Badrinarayan et al 25 . Our attempt has resulted some novel scaffolds as HITs at the top. One of the topranking compounds, ZINC13799063, a pthalimidosulfonamide derivative captured our attention, as it was the one that was spotted in our earlier attempt with DENV protease. A library of compounds was enumerated during our earlier attempt that is structurally close to ZINC13799063 and was tested for their inhibitory activity on DENV protease 26 . We utilized the same chemical library for the current exploration of antiviral activity against CV. In silico methodologies were employed to obtain a deeper insight into the possible interaction at molecular level between the most potent compound 17 and the 3C protease of CVB3 and CVB4. Since the related library was in hand, we thought of screening them. The rational behind its selection was based on the fact that sulfonamides has the ability to mimic the peptide bond and increases the resistance towards proteasecatalyzed degradation 27 . Furthermore, sulfonamides have previously been successfully incorporated in many peptidomimetics 28, 29 and have also been reported as protease inhibitors of HIV 30 and HCV 31 .
Result and Discussion

Synthesis
A small library of nineteen compounds was designed and synthesized based on the structure of one of the top hit (ZINC13799063) from the HTVS study. The designed compounds were having benzene ring in place of pyridine, a bioisosteric replacement (Figure 1) . Synthesis of the compounds was achieved by following the reactions outlined in Scheme 1. For the synthetic procedure and characterization data of the library compounds, readers are suggested to refer our earlier publication. 26 
Antiviral activity
All the nineteen compounds were evaluated for their ability to inhibit CVB3 in a classical antiviral assay. The study is designed to evaluate the dose dependent inhibition of cytopathic effect induced by CVB3 in cell culture. None was found to be effective except one, compound 17 (Table 1 ). Compound 17 inhibited CVB3 at a concentration of EC50 = 1.0 ±0.1 µM with a selectivity index of >140. Compound 17 was further evaluated against CVB4, poliovirus type1, enterovirus71 and rhinovirus14 (a small representative panel of viruses belonging to genus Enterovirus) to assess its spectrum/specificity. Interestingly it was found to inhibit only CVB4 from the representative panel at a concentration of EC50 = 16±3 µM, a concentration of 16-fold higher than it is required to inhibit CVB3. Thus, compound 17 was found to be specific towards CVB3. The carboxylic acid group at the fourth position of the phenyl ring in compound 17 seems to contribute towards its activity. Further simulation studies were performed to understand the reason for its specificity.
Molecular docking and dynamics
The antiviral data suggests that compound 17 interacts more specifically with 3C protease of CVB3 than with that of CVB4, which are very closely related proteases (65.8% similarity and 36.8% identity). Therfore, comparative molecular docking was performed to com- Table 1 . Antiviral activity against Coxsackie virus in Vero A cells 
. 3C protease residues of CVB3 were quite stable and were fluctuating less than 2.5 Å. This is comparable with the observations for CVB4, for which this is less than 2.8 Å, only slightly higher. But, the residues 40-45 of CVB4 are more flexible, where catalytic triad residue (His40) is present. This suggests that there is a possibility of these residues being more flexible may be responsible for the decrease in activity relative to CVB4. The radius of gyration (ROG) was analyzed to study protein compactness variation with simulated time. ROG of the CVB3-ligand complex ranges from 15.18 to 15.54 Å while that for the CVB4-ligand complex ranges from 15.16 to 15.52 Å, which suggests that protein/ligand complexes are stable without any noteworthy expansion/contraction in the overall protein/ligand complex ( Figure 5) . Plot of intermolecular H-bond between compound 17 and 3C proteases of CVB3 and CVB4 are given in Figure 6 . This plot suggests that, the overall H-bonding between compound 17 and 3C protease of CVB3 is relatively higher than that of CVB4. H-bond interaction with Val162, Gly164 and Asn165 play a major role for activity. Compound 17 has good Hbond interaction with the above mentioned residues for 3C protease of CVB3, whereas, for that of CVB4, although Gly164 is showing good H-bond, its interaction with remaining residues are poor, which may be one of the reason for specificity of Compound 17. Finally, energy involved for stabilizing protein-ligand complex were observed to be -4998.9 KCal/mol for 3C protease of CVB3 and -4904.3 KCal/mol for that of CVB4 ( Figure  7 and Table 2 ) which suggest that, ligand-protein complex of compound 17 with 3C protease of CVB3 is more stable than that of CVB4. These differences in the interaction of compound 17 with the 3C proteases of CVB3 and CVB4, may be resulting in a 16-fold difference in potency. Protein-ligand interactions were monitored and a histogram plot was presented in Figure 8 and the interactions were summarized Table 3 . The average protein-ligand interaction during the simulation is given in Figure 9 . The overall percentage of H-bond, ionic and hydrophobic interaction of compound 17 with 3C protease of CVB3 is better than that of CVB4, and the flexibility of residues near catalytic site of 3C protease of CVB4 may be responsible for specificity of compound 17 to CVB3 than CVB4. Table 4 summarizes the overall statistical analysis of MD simultion carried out.
Conclusion
As a result of this study, a novel antiviral compound with a benzene sulfonamide skeleton was obtained using in silico strategies based on the crystal structure of the 3C protease of Coxsackie virus B3. A series of nineteen novel benzene sulfonamide derivatives were synthesized and the evaluation of the antiviral activity in a virus-cell-based assay provided compound 17, a potent and specific inhibitor of CVB3. MD simulation studies demonstrated that the difference in activity between CVB3 & CVB4 is mainly attributed to the difference in H-bond, ionic bond and hydrophobic interactions of compound 17 towards CVB3 and CVB4 along with flexibility near catalytic residue His40 of 3C protease of CVB3/CVB4. Before embarking in further biological studies to confirm that the 3C protease is the target of compound 17 & to further investigate its precise molecular mechanism of action, additional molecules will need to be synthesized in order to obtain inhibitors with antiviral activity in the sub-micromolar range, which will facilitate such studies. Furthermore, the synthesis of additional compounds will also allow to explore whether or not this series of compounds can be modified as such that compounds can be obtained with antiviral activity against a broader spectrum of enteroviruses. 
Res % Interaction for CVB4 H-bond H2O bridge Hydrophobic Ionic
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Chemistry
For the synthetic procedure and characterization data of the library compounds (1-19), readers are suggested to refer our earlier publication 26 .
Virus-cell-based assays
Coxsackievirus B3 strain Nancy and enterovirus 71 strain BRCR were obtained from F. Van Kuppeveld (University of Utrecht, The Netherlands), Coxsackievirus B4 strain E2 Edwards was received from J.W. Joon (University of Calgary, Canada), poliovirus 1 strain Sabin from A.J. Macadam (NIBSC, UK), and rhinovirus type 14 from K. Andries (J&J, Belgium). Vero A, RD (ECACC85111502), HeLa Rh or BGM cells were sub-cultured in cell growth medium [MEM Rega3 medium (Life Technologies, Cat. N° 19993013) with FCS (10%; Gibco), L-glutamine (5 mL, 200 mM; Gibco, 25030024) and NaHCO3 (0.075%; Gibco, 25080060)]. They are prepared in tissue culture flasks (150 cm 2 , Techno Plastic products) at a ratio of 1:10 (RD, HeLa Rh) or 1:4 (Vero A and BGM) and kept for 3-4 days or for 7 days before harvesting. The antiviral assays were performed in the same medium with only 2% FCS and in case of rhinovirus, medium with 30mM MgCl2 was used. One day prior to assay setup, the cells were seeded in assay medium in 96-well microtiter plates (Falcon, BD) at a density of 25.000 cells/well in medium and allowed to adhere overnight in an incubator (37 of 25.000 cell-99% RH). The next day, a 2x compound dilution series was prepared in the medium present on top of the cells after which 100 µL medium (treated, uninfected controls) or 100 mL of a 2x virus inoculum (a virus dilution that was normalized to be as low as possible and still to induce a full cytopathic effect at the desired assay end point) was added. After setup, the assay plates were returned to the incubator for 3-4 days, a time at which maximal cytopathic effect is observed in the untreated, infected control conditions. For the quantification of the antiviral and antimetabolic effects, the assay medium was aspirated, followed by addition of 75 μL of a 5% MTS (Promega) solution in phenol red-free medium and incubation for 1.5 h (37 °C, 5% CO2, 95-99% relative humidity) until an optical density (OD value) in the range of 0.6-0.8 was obtained. Absorbance was recorded at a wavelength of 498 nm (Safire², Tecan) and converted to percentage of untreated controls. Analysis of the raw data, quality control and calculation of the EC50 value was performed employing a custommade data processing software package (Accelrys). The EC50 (value derived from the dose-response curve) represents the concentrations at which 50% inhibition of virus-induced cell death is observed. A compound is only considered as a selective inhibitor of virus replication when at least at one concentration, full inhibition of virus-induced cell death is observed without any apparent effect on host cell or monolayer morphology after microscopic inspection.
Molecular docking
The structure of the compound 17 was sketched using "build" tool while ZINC12 download from web (www.zinc-docking.org, drug-like subset filtered further using openeye FILTER tool) and prepared for docking using "Ligprep" utility (employing default parameters) in Maestro-9.3 (Schrodinger LLC). X-ray crystal structure of the CVB3 protease (PDB: 3ZZA 32 ) was downloaded from the protein databank (http://www.rcsb.org/pdb). As crystal structure for CVB4 protease was not available, it is modeled through "Prime" module in Maestro-9.3 using the CVB4 protease sequence (UniprotKB AC: Q86887||15392-1720) 33 and the X-ray crystal structure of 3C protease of human Enterovirus 93 (PDB Code: 3Q3Y) 34 as they are having a sequence identity of 96%. Both the proteins were prepared for docking using "Protein preparation wizard" (employing default parameters) and grid was generated for docking using "Receptor grid generation" (grid box dimension 30Åx30Åx30Å centred over catalytic triad) module in Maestro-9.3.
Ligand docking was performed using Glide tool implemented in Maestro-9.3. For high-throughput virtual screening of ligands from ZINC12 database, HTVS protocol in Glide was employed. From the top 100 hits, different scaffolds are manually picked (Figure xx) . A pthalimido-sulfonamide was chosen for enumeration of a small chemical library (Table 1) . For compound 17, XP protocol in Glide was employed. In both the cases default parameters were used for study.
Molecular dynamics
Docked conformer of compound 17 with 3C protease of CVB3 and CVB4 were used for further Molecular dynamic simulation with 'Desmond v3.6 Package' 35 . Predefined TIP3P water model 36 was used to simulate water molecules using OPLS2005 force field 37 . Orthorhombic periodic boundary conditions were set up to specify the shape and size of the repeating unit buffered at 10 Å distances. Boundary conditions box volume was initially calculated as 251853 Å 3 and 229072 Å 3 before and after minimization respectively. To neutralize the system electrically, three chloride ions were added to balance the charge of the system and were placed at random positions in the solvated system. After building the solvated system containing the protein in complex with the ligand, the system was minimized and relaxed using the default protocol integrated within Desmond module with OPLS 2005 force field parameters. Molecular dynamic simulations were carried out with the periodic boundary conditions in the NPT ensemble 38 . The temperature and pressure were kept at 300 K and 1.01325 atmospheric pressure using Nose-Hoover temperature coupling and isotropic scaling 39 , the operation was followed by running the 30 ns NPT production simulation and saving the configurations thus obtained at 5 ps intervals.
